BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 19546477)

  • 1. A comparison of neurocognitive functioning in children previously randomized to dexamethasone or prednisone in the treatment of childhood acute lymphoblastic leukemia.
    Kadan-Lottick NS; Brouwers P; Breiger D; Kaleita T; Dziura J; Liu H; Chen L; Nicoletti M; Stork L; Bostrom B; Neglia JP
    Blood; 2009 Aug; 114(9):1746-52. PubMed ID: 19546477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cognitive sequelae in children treated for acute lymphoblastic leukemia with dexamethasone or prednisone.
    Waber DP; Carpentieri SC; Klar N; Silverman LB; Schwenn M; Hurwitz CA; Mullenix PJ; Tarbell NJ; Sallan SE
    J Pediatr Hematol Oncol; 2000; 22(3):206-13. PubMed ID: 10864051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does dexamethasone induce more neuropsychological side effects than prednisone in pediatric acute lymphoblastic leukemia? A systematic review.
    Warris LT; van den Heuvel-Eibrink MM; den Hoed MA; Aarsen FK; Pieters R; van den Akker EL
    Pediatr Blood Cancer; 2014 Jul; 61(7):1313-8. PubMed ID: 24532490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypothalamic-pituitary-adrenal (HPA) axis suppression after treatment with glucocorticoid therapy for childhood acute lymphoblastic leukaemia.
    Rensen N; Gemke RJ; van Dalen EC; Rotteveel J; Kaspers GJ
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD008727. PubMed ID: 29106702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropsychological outcomes of a randomized trial of prednisone versus dexamethasone in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute All Consortium Protocol 00-01.
    Waber DP; McCabe M; Sebree M; Forbes PW; Adams H; Alyman C; Sands SA; Robaey P; Romero I; Routhier MÈ; Girard JM; Sallan SE; Silverman LB
    Pediatr Blood Cancer; 2013 Nov; 60(11):1785-91. PubMed ID: 23832430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bony morbidity in children treated for acute lymphoblastic leukemia.
    Strauss AJ; Su JT; Dalton VM; Gelber RD; Sallan SE; Silverman LB
    J Clin Oncol; 2001 Jun; 19(12):3066-72. PubMed ID: 11408503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukoencephalopathy and long-term neurobehavioural, neurocognitive, and brain imaging outcomes in survivors of childhood acute lymphoblastic leukaemia treated with chemotherapy: a longitudinal analysis.
    Cheung YT; Sabin ND; Reddick WE; Bhojwani D; Liu W; Brinkman TM; Glass JO; Hwang SN; Srivastava D; Pui CH; Robison LL; Hudson MM; Krull KR
    Lancet Haematol; 2016 Oct; 3(10):e456-e466. PubMed ID: 27658980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of neurocognitive functioning to quality of life after childhood acute lymphoblastic leukemia.
    Kunin-Batson A; Kadan-Lottick N; Neglia JP
    Psychooncology; 2014 Jun; 23(6):692-9. PubMed ID: 24497266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HRQOL implications of treatment with dexamethasone for children with acute lymphoblastic leukemia (ALL).
    Eiser C; Davies H; Jenney M; Stride C; Glaser A
    Pediatr Blood Cancer; 2006 Jan; 46(1):35-9. PubMed ID: 15926164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adaptive functioning and academic achievement in survivors of childhood acute lymphoblastic leukemia: A report from the Children's Oncology Group.
    Jacola LM; Baran J; Noll RB; Willard VW; Hardy KK; Embry L; Hullmann SE; Larsen EC; Winick N; Kairalla JA
    Pediatr Blood Cancer; 2021 Apr; 68(4):e28913. PubMed ID: 33522102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of neurocognitive functioning in children previously randomly assigned to intrathecal methotrexate compared with triple intrathecal therapy for the treatment of childhood acute lymphoblastic leukemia.
    Kadan-Lottick NS; Brouwers P; Breiger D; Kaleita T; Dziura J; Northrup V; Chen L; Nicoletti M; Bostrom B; Stork L; Neglia JP
    J Clin Oncol; 2009 Dec; 27(35):5986-92. PubMed ID: 19884541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteonecrosis as a complication of treating acute lymphoblastic leukemia in children: a report from the Children's Cancer Group.
    Mattano LA; Sather HN; Trigg ME; Nachman JB
    J Clin Oncol; 2000 Sep; 18(18):3262-72. PubMed ID: 10986059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
    Bostrom BC; Sensel MR; Sather HN; Gaynon PS; La MK; Johnston K; Erdmann GR; Gold S; Heerema NA; Hutchinson RJ; Provisor AJ; Trigg ME;
    Blood; 2003 May; 101(10):3809-17. PubMed ID: 12531809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obesity after successful treatment of acute lymphoblastic leukemia in childhood.
    Van Dongen-Melman JE; Hokken-Koelega AC; Hählen K; De Groot A; Tromp CG; Egeler RM
    Pediatr Res; 1995 Jul; 38(1):86-90. PubMed ID: 7478803
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steroid withdrawal syndrome during steroid tapering in childhood acute lymphoblastic leukemia: a controlled study comparing prednisone versus dexamethasone in induction phase.
    Saracco P; Bertorello N; Farinasso L; Einaudi S; Barisone E; Altare F; Corrias A; Pastore G
    J Pediatr Hematol Oncol; 2005 Mar; 27(3):141-4. PubMed ID: 15750445
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Results and conclusions of the European Intergroup EURO-LB02 trial in children and adolescents with lymphoblastic lymphoma.
    Landmann E; Burkhardt B; Zimmermann M; Meyer U; Woessmann W; Klapper W; Wrobel G; Rosolen A; Pillon M; Escherich G; Attarbaschi A; Beishuizen A; Mellgren K; Wynn R; Ratei R; Plesa A; Schrappe M; Reiter A; Bergeron C; Patte C; Bertrand Y
    Haematologica; 2017 Dec; 102(12):2086-2096. PubMed ID: 28983060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000.
    Möricke A; Zimmermann M; Valsecchi MG; Stanulla M; Biondi A; Mann G; Locatelli F; Cazzaniga G; Niggli F; Aricò M; Bartram CR; Attarbaschi A; Silvestri D; Beier R; Basso G; Ratei R; Kulozik AE; Lo Nigro L; Kremens B; Greiner J; Parasole R; Harbott J; Caruso R; von Stackelberg A; Barisone E; Rössig C; Conter V; Schrappe M
    Blood; 2016 Apr; 127(17):2101-12. PubMed ID: 26888258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substituting dexamethasone for prednisone complicates remission induction in children with acute lymphoblastic leukemia.
    Hurwitz CA; Silverman LB; Schorin MA; Clavell LA; Dalton VK; Glick KM; Gelber RD; Sallan SE
    Cancer; 2000 Apr; 88(8):1964-9. PubMed ID: 10760775
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroanatomical abnormalities related to dexamethasone exposure in survivors of childhood acute lymphoblastic leukemia.
    Phillips NS; Cheung YT; Glass JO; Scoggins MA; Liu W; Ogg RJ; Mulrooney DA; Pui CH; Robison LL; Reddick WE; Hudson MM; Krull KR
    Pediatr Blood Cancer; 2020 Mar; 67(3):e27968. PubMed ID: 31407461
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dexamethasone-associated toxicity during induction chemotherapy for childhood acute lymphoblastic leukemia is augmented by concurrent use of daunomycin.
    Belgaumi AF; Al-Bakrah M; Al-Mahr M; Al-Jefri A; Al-Musa A; Saleh M; Salim MF; Osman M; Osman L; El-Solh H
    Cancer; 2003 Jun; 97(11):2898-903. PubMed ID: 12767105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.